Longevity study with low doses of selegiline/(−)-deprenyl and (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP)

摘要: Abstract Aims: The first longevity study demonstrating that rats treated with the MAO-B inhibitory dose of (−)-deprenyl (0.25 mg/kg) lived significantly longer than their saline-treated peers was published in 1988, and corroborated many papers. recent findings is primarily a PEA-derived synthetic catecholaminergic activity enhancer substance; (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP) tryptamine-derived substance, initiated our on low doses BPAP to test effect's role life extension. Main methods: We used shuttle box technique for selecting optimum BPAP. (−)-Deprenyl exerts 0.001 mg/kg its ‘specific’ effect 0.1 mg/kg ‘non-specific’ effect. 0.0001 mg/kg 0.05 mg/kg. Groups male Wistar (N = 40) were subcutaneously from 10th week until death, three times weekly, saline (0.5 ml/kg), selected or BPAP, respectively. As an indicator aging we tested age-related changes learning ability. Key findings: Rats 0.0001 0.05 mg/kg (P  Significance revealed responsible